{"altmetric_id":13711066,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["the_body"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa6073cf058f610006922","authors":["BroderGail B."],"doi":"10.1089\/aid.2014.5198.abstract","endpage":"A106","first_seen_on":"2016-11-16T23:11:23+00:00","issns":["0889-2229","1931-8405"],"issue":"S1","journal":"AIDS Research and Human Retroviruses","last_mentioned_on":1479337816,"links":["http:\/\/online.liebertpub.com\/doi\/pdfplus\/10.1089\/aid.2014.5198.abstract"],"pmid":"25357291","pubdate":"2014-10-14T23:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Immunology and Microbiology"],"startpage":"A105","subjects":["acquiredimmunodeficiencysyndrome"],"title":"Implementing Good Participatory Practice (GPP) in HVTN505 - The HIV Vaccine Trials Network (HVTN) Experience","type":"article","volume":"30 Suppl 1"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7700472,"mean":6.6097995325169,"rank":1062390,"this_scored_higher_than_pct":85,"this_scored_higher_than":6569208,"rank_type":"exact","sample_size":7700472,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":208542,"mean":13.121555348828,"rank":44934,"this_scored_higher_than_pct":77,"this_scored_higher_than":160753,"rank_type":"exact","sample_size":208542,"percentile":77},"this_journal":{"total_number_of_other_articles":772,"mean":2.9791102464332,"rank":39,"this_scored_higher_than_pct":94,"this_scored_higher_than":729,"rank_type":"exact","sample_size":772,"percentile":94},"similar_age_this_journal_3m":{"total_number_of_other_articles":17,"mean":2.396875,"rank":2,"this_scored_higher_than_pct":88,"this_scored_higher_than":15,"rank_type":"exact","sample_size":17,"percentile":88}}},"demographics":[],"posts":{"news":[{"title":"Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?","url":"http:\/\/ct.moreover.com\/?a=28630340512&p=1pl&v=1&x=br4aEriwuDZsAj2pHawxQQ","license":"public","citation_ids":[9962033,4301488,13711064,13711066],"posted_on":"2016-11-16T23:10:16+00:00","summary":"Credit: DanielVilleneuve for iStock via Thinkstock Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe\u2026","author":{"name":"The Body","url":"http:\/\/www.thebody.com\/index.html?ic=3002","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/002\/532\/normal\/Screen_Shot_2016-10-26_at_09.58.02.png?1477472339"}}]}}